CD274 and non-small cell lung carcinoma: Thirdly, in ex vivo analysis, the PD-L1 status of cancer cells is assessed using primary antibodies for biological research, while the other PD-L1 diagnostic immunohistochemical assay systems tailored for each immune checkpoint inhibitor are recommended to determine patient eligibility for immunotherapy treatment of NSCLC in the current clinical setting.